转基因短QT综合征1型兔重现人类疾病表型:心房心室QT/动作电位时程缩短及室速/室颤诱发率增加
本研究通过卵母细胞显微注射β-肌球蛋白重链启动子-KCNH2/HERG-N588K构建体,生成转基因短QT综合征1型(SQT1)兔,并在体内外评估电生理特征。SQT1兔QT间期缩短、QT/RR斜率变浅,心房和心室不应期及动作电位时程缩短,室速/室颤诱发率增加,奎尼丁可延长并正常化QT及动作电位时程。
要点
- SQT1兔QT间期较野生型缩短(147.8±2 ms vs. 166.4±3 ms,P<0.0001)。
- SQT1兔心室动作电位时程vAPD90缩短(118.6±5 ms vs. 154.4±2 ms,P<0.0001)。
- 奎尼丁通过抑制IKr延长并正常化SQT1兔QT及动作电位时程。
核心结论
- SQT1兔在QT/动作电位时程缩短及室速/室颤诱发率增加方面重现人类疾病表型,并对奎尼丁显示类似有益反应。
研究设计与样本
- 通过卵母细胞显微注射β-肌球蛋白重链启动子-KCNH2/HERG-N588K构建体生成转基因SQT1兔,与野生型同窝兔对照。
- 对SQT1和野生型兔进行在体心电图、电生理研究、磁共振成像及离体动作电位测量。
- 采用膜片钳、实时PCR和蛋白质印迹评估电重构。
主要发现
- SQT1兔QT间期较野生型缩短(147.8±2 ms vs. 166.4±3 ms,P<0.0001),QT/RR斜率更浅。
- SQT1兔心房和心室不应期及动作电位时程缩短(vAPD90,118.6±5 ms vs. 154.4±2 ms,P<0.0001)。
- SQT1兔室速/室颤诱发率增加,收缩功能未改变但舒张松弛增强。
- SQT1兔IKr稳态电流增加且失活受损,而IKr尾电流减少。
- SQT1兔中IK1降低部分逆转表型,IKs小幅增加可能部分加重表型。
临床怎么用
- 该模型可用于阐明SQT1心律失常发生机制及识别新型抗心律失常策略。
- 奎尼丁通过减少IKr延长并正常化SQT1兔QT及动作电位时程,提示潜在治疗价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Short-QT syndrome 1 (SQT1) is an inherited channelopathy with accelerated repolarization due to gain-of-function in HERG/IKr. Patients develop atrial fibrillation, ventricular tachycardia (VT), and sudden cardiac death with pronounced inter-individual variability in phenotype. We generated and characterized transgenic SQT1 rabbits and investigated electrical remodelling. METHODS AND RESULTS: Transgenic rabbits were generated by oocyte-microinjection of β-myosin-heavy-chain-promoter-KCNH2/HERG-N588K constructs. Short-QT syndrome 1 and wild type (WT) littermates were subjected to in vivo ECG, electrophysiological studies, magnetic resonance imaging, and ex vivo action potential (AP) measurements. Electrical remodelling was assessed using patch clamp, real-time PCR, and western blot. We generated three SQT1 founders. QT interval was shorter and QT/RR slope was shallower in SQT1 than in WT (QT, 147.8 ± 2 ms vs. 166.4 ± 3, P < 0.0001). Atrial and ventricular refractoriness and AP duration were shortened in SQT1 (vAPD90, 118.6 ± 5 ms vs. 154.4 ± 2, P < 0.0001). Ventricular tachycardia/fibrillation (VT/VF) inducibility was increased in SQT1. Systolic function was unaltered but diastolic relaxation was enhanced in SQT1. IKr-steady was increased with impaired inactivation in SQT1, while IKr-tail was reduced. Quinidine prolonged/normalized QT and action potential duration (APD) in SQT1 rabbits by reducing IKr. Diverse electrical remodelling was observed: in SQT1, IK1 was decreased-partially reversing the phenotype-while a small increase in IKs may partly contribute to an accentuation of the phenotype. CONCLUSION: Short-QT syndrome 1 rabbits mimic the human disease phenotype on all levels with shortened QT/APD and increased VT/VF-inducibility and show similar beneficial responses to quinidine, indicating their value for elucidation of arrhythmogenic mechanisms and identification of novel anti-arrhythmic strategies.
引用
- Odening KE, Bodi I, Franke G, et al. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility. Eur Heart J. 2019. PMID: 30496390. doi:10.1093/eurheartj/ehy761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。